[
    [
        {
            "time": "",
            "original_text": "国产新冠疫苗迎“收获期”，龙头企业三季度业绩暴涨",
            "features": {
                "keywords": [
                    "新冠疫苗",
                    "收获期",
                    "龙头企业",
                    "三季度",
                    "业绩暴涨"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国产新冠疫苗迎“收获期”，龙头企业三季度业绩暴涨",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "康泰生物：吸附无细胞百白破（组分）联合疫苗，适用于2月龄及以上的婴幼儿，用于预防百日咳、白喉、破伤风",
            "features": {
                "keywords": [
                    "康泰生物",
                    "百白破疫苗",
                    "婴幼儿",
                    "预防"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "康泰生物：吸附无细胞百白破（组分）联合疫苗，适用于2月龄及以上的婴幼儿，用于预防百日咳、白喉、破伤风",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "康泰生物：冻干人用狂犬病疫苗（人二倍体细胞）按照新的《药品注册管理办法（2020年）》在申请药品注册批件中",
            "features": {
                "keywords": [
                    "康泰生物",
                    "狂犬病疫苗",
                    "药品注册管理办法",
                    "2020年"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "康泰生物：冻干人用狂犬病疫苗（人二倍体细胞）按照新的《药品注册管理办法（2020年）》在申请药品注册批件中",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "康泰生物：公司三季度存货较年初增加，主要是公司经营规模扩大，本报告期产成品、原材料增加所致",
            "features": {
                "keywords": [
                    "康泰生物",
                    "三季度",
                    "存货",
                    "经营规模",
                    "产成品",
                    "原材料"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物：公司三季度存货较年初增加，主要是公司经营规模扩大，本报告期产成品、原材料增加所致",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 4,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "康泰生物：新冠灭活疫苗III期临床试验6月下旬在海外进行第一针接种，目前在有序进行中",
            "features": {
                "keywords": [
                    "康泰生物",
                    "新冠灭活疫苗",
                    "III期临床试验",
                    "6月下旬",
                    "海外"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物：新冠灭活疫苗III期临床试验6月下旬在海外进行第一针接种，目前在有序进行中",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "新疫苗获批叠加业绩增长130% 康泰生物股价为何开启“下跌模式”",
            "features": {
                "keywords": [
                    "新疫苗",
                    "获批",
                    "业绩增长",
                    "130%",
                    "康泰生物",
                    "股价",
                    "下跌模式"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "新疫苗获批叠加业绩增长130% 康泰生物股价为何开启“下跌模式”",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        }
    ]
]